Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone palmitate deltoid versus gluteal injection crossover safety study in schizophrenia
2005-001845-40Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2005
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of paliperidone palmitate and paliperidone in schizophrenia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Tolerance of initiation, Tolerance of switching and 1 more. Started Jun 2005; status: completed.
02
Drugs
paliperidone palmitatepaliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2005-001845-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001845-40.